Allogene Therapeutics (ALLO) EPS (Weighted Average and Diluted): 2019-2025
Historic EPS (Weighted Average and Diluted) for Allogene Therapeutics (ALLO) over the last 6 years, with Sep 2025 value amounting to -$0.19.
- Allogene Therapeutics' EPS (Weighted Average and Diluted) rose 40.62% to -$0.19 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.98, marking a year-over-year increase of 37.18%. This contributed to the annual value of -$1.32 for FY2024, which is 36.84% up from last year.
- Per Allogene Therapeutics' latest filing, its EPS (Weighted Average and Diluted) stood at -$0.19 for Q3 2025, which was up 17.39% from -$0.23 recorded in Q2 2025.
- Allogene Therapeutics' EPS (Weighted Average and Diluted)'s 5-year high stood at $0.01 during Q4 2021, with a 5-year trough of -$0.69 in Q1 2023.
- Its 3-year average for EPS (Weighted Average and Diluted) is -$0.38, with a median of -$0.35 in 2024.
- Per our database at Business Quant, Allogene Therapeutics' EPS (Weighted Average and Diluted) soared by 100.93% in 2021 and then slumped by 6,900.00% in 2022.
- Allogene Therapeutics' EPS (Weighted Average and Diluted) (Quarterly) stood at $0.01 in 2021, then crashed by 6,900.00% to -$0.68 in 2022, then rose by 25.00% to -$0.51 in 2023, then soared by 45.10% to -$0.28 in 2024, then surged by 40.62% to -$0.19 in 2025.
- Its EPS (Weighted Average and Diluted) stands at -$0.19 for Q3 2025, versus -$0.23 for Q2 2025 and -$0.28 for Q1 2025.